FDA Approval Summary: Tovorafenib for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma.
Singh S, Bradford D, Chatterjee S, Li X, Aungst SL, Skinner AM, Miller CP, Kim-McOlash S, Fourie Zirkelbach J, Xiong Y, Bi Y, Wang YH, Yang Y, Sun J, Kraft J, Charlab R, Shord SS, Tang S, Scepura B, Bulatao I, Udoka O, Saber H, Rahman NA, Pazdur R, Singh H, Donoghue M, Drezner N.
Singh S, et al. Among authors: wang yh.
Clin Cancer Res. 2025 Jan 14. doi: 10.1158/1078-0432.CCR-24-3439. Online ahead of print.
Clin Cancer Res. 2025.
PMID: 39808502